Health Economics

This section of the ESCEO web site, devoted to health economics, will provide, on a regular basis, expert opinion, consensus statements and reprints of papers that either are produced by members of our Scientific Committee or that members of our Scientific Committee found of particular interest to the ESCEO members. The scope includes cost-effectiveness of interventions and the burden of disease from an economic perspective. Our objective is to provide you with clear and up-to-date, scientifically reliable information dealing with topics that are directly linked with the goals and missions of ESCEO.

Publications


Download Title Authors
The cost-effectiveness of alendronate in the management of osteoporosis J. A. Kanis, J. Adams, F. Borgström, C. Cooper, Bengt Jönsson, D. Preedy, P. Selby, J. Compston.
Reply to Letter to the Editor: Modelling cost-effectiveness in osteoporosis J. A. Kanis, J. Adams, F. Borgström, C. Cooper, Bengt Jönsson, D. Preedy, P. Selby, J. Compston.
An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting F. Borgström, B. Jönsson, O. Ström, J. A. Kanis
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective F. Borgström . Å. Carlsson . H. Sintonen . S. Boonen . P. Haentjens . R. Burge . O. Johnell . B. Jönsson . J. A. Kanis
At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis F. Borgström; O. Johnell, J. A. Kanis, B. Jönsson, C. Rehnberg
Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: Results based on the Women's Health Initiative randomized controlled trial N. Zethraeus, F. Borgström, B. Jönsson, J. A. Kanis
Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK - Results based on the Women's Health Initiative randomised controlled trial I. Lekander, F. Borgström, O. Ström, N. Zethraeus, J. A. Kanis
Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK I. Lekander, F. Borgström, O. Ström, N. Zethraeus, J. A. Kanis
Glucocorticoid-induced osteoporosis: a systematic review and cost - utility analysis J. A. Kanis, JE. Brazier, MD. Stevenson, E.V. McCloskey, S. Davis, M. Lloyd-Jones
Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women MD. Stevenson, JE Brazier, NW Calvert, M. Lloyd-Jones, JE Oakley, J. A. Kanis
Incorporating adherence into health economic modelling of osteoporosis O. Ström, F. Borgström, J. A. Kanis, B. Jönsson
Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model N. Zethraeus, F. Borgström, O. Ström, J. A. Kanis, B. Jönsson
The Cost-Effectiveness of Bisphosphonates in Postmenopausal Women Based on Individual Long-Term Fracture Risks T.-P. van Staa, J. A. Kanis, P. Geusens, A. Boonen, H. G. M. Leufkens, C. Cooper
Utility Values Associated with Osteoporotic Fracture: A Systematic Review of the Literature M. Hiligsmann, O. Ethgen, F. Richy, J.-Y. Reginster
Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications M. Hiligsmann, V. Rabenda, H.-J. Gathon, O. Ethgen, J.-Y. Reginster
Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis M. Hiligsmann, O. Ethgen, O. Bruyere, F. Richy, H.-J. Gathon, J.-Y. Reginster
An Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for the Identification of Patients with Osteoporosis M. Hiligsmann, O. Ethgen, O. Bruyere, J.-Y. Reginster
Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years M. Hiligsmann, O. Bruyere, J.-Y. Reginster
Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women M. Hiligsmann, O. Bruyere, J.-Y. Reginster
The need for economic evaluation in osteoarthritis O. Bruyere, J.-Y. Reginster
Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis O. Bruyere, S. Scholtissen, A. Neuprez, M. Hiligsmann, A. Toukouki, J.-Y. Reginster
The risk and burden of vertebral fractures in Sweden J.A. Kanis, O. Johnell, A. Oden, F. Borgstrom, N. Zethraeus, C. De Laet, B. Jonsson
The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients M. Hiligsmann, V. Rabenda, O. Bruyere, J.-Y. Reginster
Cost-Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence M. Hiligsmann, H.-J. Gathon, O. Bruyere, O. Ethgen, V. Rabenda, J.-Y. Reginster